An Integrated Genomic Analysis of Human Glioblastoma Multiforme

D. Williams Parsons(Howard Hughes Medical Institute), Siân Jones(Howard Hughes Medical Institute), Xiaosong Zhang(Howard Hughes Medical Institute), Jimmy Lin(Howard Hughes Medical Institute), Rebecca Leary(Howard Hughes Medical Institute), Philipp Angenendt(Howard Hughes Medical Institute), Parminder K. Mankoo(Howard Hughes Medical Institute), Hannah Carter(Howard Hughes Medical Institute), I‐Mei Siu(Howard Hughes Medical Institute), Gary L. Gallia(Howard Hughes Medical Institute), Alessandro Olivi(Howard Hughes Medical Institute), Roger E. McLendon(Howard Hughes Medical Institute), B. Ahmed Rasheed(Howard Hughes Medical Institute), Stephen T. Keir(Howard Hughes Medical Institute), Tatiana Nikolskaya(Howard Hughes Medical Institute), Yuri Nikolsky(Howard Hughes Medical Institute), Dana Busam(Howard Hughes Medical Institute), Hanna Tekleab(Howard Hughes Medical Institute), Luis A. Díaz(Howard Hughes Medical Institute), James Hartigan(Howard Hughes Medical Institute), Doug Smith(Howard Hughes Medical Institute), Robert L. Strausberg(Howard Hughes Medical Institute), Suely Kazue Nagahashi Marie(Howard Hughes Medical Institute), Sueli Mieko Oba‐Shinjo(Howard Hughes Medical Institute), Hai Yan(Howard Hughes Medical Institute), Gregory J. Riggins(Howard Hughes Medical Institute), Darell D. Bigner(Howard Hughes Medical Institute), Rachel Karchin(Howard Hughes Medical Institute), Nick Papadopoulos(Howard Hughes Medical Institute), Giovanni Parmigiani(Howard Hughes Medical Institute), Bert Vogelstein(Howard Hughes Medical Institute), Victor E. Velculescu(Howard Hughes Medical Institute), Kenneth W. Kinzler(Howard Hughes Medical Institute)
Science
September 4, 2008
Cited by 5,840Open Access
Full Text

Abstract

Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.


Related Papers

No related papers found

Powered by citation graph analysis